Life sciences companies are frequent targets of securities litigation. Often, when a company discloses bad news about a developing device or drug, the company’s stock price drops and pl...
On November 17, the U.S. Court of Appeals for the Third Circuit, based in Philadelphia, held that noteholders were entitled to payment of an optional redemption premium at the make-whole ...
On November 18, the SEC’s Division of Corporation Finance published new guidance relating to its 2015 no-action letter on 5-day debt tender and exchange offers, and also provided guidan...
On September 28, in a long-anticipated move, the SEC proposed to shorten the standard settlement cycle for most broker-dealer transactions to two business days after the trade date (T+2) ...
We recently published a survey of corporate governance practices adopted by companies in their IPOs
. Our survey concluded that IPO companies continue to adopt charter provisions such as...
Last Wednesday, the SEC issued a proposal aimed at eliminating or updating duplicative, overlapping and obsolete disclosure requirements. The proposal is welcome, but largely technical in...
Spurred by a provision in the Dodd-Frank Act of 2010, in August 2012 the SEC adopted rules requiring companies to disclose payments made to governments in order to further oil, natural ga...
On June 16, the SEC proposed rules aimed at overhauling and modernizing disclosure requirements for companies with material mining operations (excluding oil and gas) as part of its ongoin...
With ongoing pressure on companies that are past the IPO stage to update or modify their corporate governance practices to align with the views of some shareholders and proxy advisory fir...
On May 17, the staff of the SEC’s Division of Corporation Finance released new and revised Compliance and Disclosure Interpretations (C&DIs) on the use of non-GAAP financial measures. C...
